Clinical experience with high-flow nasal cannulas for coronavirus disease 2019 patients in Japan

Katsuno, Takashi; Suzuki, Manabu; Hojo, Masayuki; Terada, Junko; Nakamura, Keiji; Suzuki, T.; Miyazato, Yusuke; Sugiyama, Haruhito

doi:10.1016/j.resinv.2021.02.011

Cited by 10 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, the HFNC treatment is conditionally possible if a patient is managed in a negative-pressure private room or in the red zone and uses a surgical mask and if the medical practitioner has appropriate infection control with full personal protective equipment [ 5 ]. Under these conditions, a recent online questionnaire survey by the Japanese Respiratory Society revealed that the use of HFNC treatment in COVID-19 cases in Japan had increased, partly due to the limited availability of medical resources during the larger 3 rd wave coupled with increased internal reports on the success of the HFNC treatment [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

High-flow nasal cannula oxygen therapy in hypoxic patients with COVID-19 pneumonia: A retrospective cohort study confirming the utility of respiratory rate index

Takeshita

Terada

Hirasawa

et al. 2022

Respiratory Investigation

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

High-flow nasal cannula oxygen therapy in hypoxic patients with COVID-19 pneumonia: A retrospective cohort study confirming the utility of respiratory rate index

Takeshita

Terada

Hirasawa

et al. 2022

Respiratory Investigation

View full text Add to dashboard Cite

“…After excluding duplicates and evaluating the full texts of articles, we identified 25 eligible studies (1 RCT, 12 case-control studies, and 12 cohort studies). 14 – 38 The search and screening process is described in Figure 1 . The main characteristics of the articles included in the meta-analysis are shown in Tables 1 , 2 , 3 and 4 .…”

Section: Resultsmentioning

confidence: 99%

“…A total of 586 out of 2055 patients on HFNC from 20 studies 14 , 16 – 24 , 26 – 28 , 30 , 33 – 38 ultimately died, for a mortality rate of 0.23 (95% CI: 0.19–0.29, I 2 = 88%; Figure 3 (b) ) . A total of 529 out of 1124 patients from 14 studies 14 , 16 – 18 , 20 , 23 , 24 , 26 , 29 , 30 , 33 , 35 , 36 , 38 experienced HFNC failure (escalation to NIV or intubation and/or death), for a failure rate of 0.47 (95% CI: 0.42–0.51, I 2 = 56%; Figure 3 (c) ) . When reported, the ROX index after the initiation of HFNC was 5.0 ± 2.4, the duration of HFNC was 4.9 ± 5.0 days, and the length of the hospital stay was 19.6 ± 13.6 days.…”

Section: Resultsmentioning

confidence: 99%

“…As shown in Table 5, a total of 1076 out of 2482 patients on HFNC from 24 studies 14–30,32–38 ultimately received invasive mechanical ventilation, for a pooled intubation rate of 0.44 (95% CI: 0.38–0.51, I 2 = 84%; Figure 3( a) ). A total of 586 out of 2055 patients on HFNC from 20 studies 14,16–24,26–28,30,33–38 ultimately died, for a mortality rate of 0.23 (95% CI: 0.19–0.29, I 2 = 88%; Figure 3 (b) ). A total of 529 out of 1124 patients from 14 studies 14,16–18,20,23,24,26,29,30,33,35,36,38 experienced HFNC failure (escalation to NIV or intubation and/or death), for a failure rate of 0.47 (95% CI: 0.42–0.51, I 2 = 56%; Figure 3 (c) ).…”

Section: Resultsmentioning

confidence: 99%

“…47 In the studies included in this meta-analysis and in other studies, some measures such as negative-pressure rooms, high-energy particulate accumulator filters, adequate personal protective equipment, and surgical masks may be sufficient to protect staff. 13 , 30 , 35 , 48 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of the use of a high-flow nasal cannula to treat COVID-19 patients and risk factors for failure: a meta-analysis

Dai

Tan

et al. 2022

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) has spread globally, and many patients with severe cases have received oxygen therapy through a high-flow nasal cannula (HFNC). Objectives: We assessed the efficacy of HFNC for treating patients with COVID-19 and risk factors for HFNC failure. Methods: We searched PubMed, Embase, and the Cochrane Central Register of randomized controlled trials (RCTs) and observational studies of HFNC in patients with COVID-19 published in English from January 1st, 2020 to August 15th, 2021. The primary aim was to assess intubation, mortality, and failure rates in COVID-19 patients supported by HFNC. Secondary aims were to compare HFNC success and failure groups and to describe the risk factors for HFNC failure. Results: A total of 25 studies fulfilled selection criteria and included 2851 patients. The intubation, mortality, and failure rates were 0.44 (95% confidence interval (CI): 0.38–0.51, I2 = 84%), 0.23 (95% CI: 0.19–0.29, I2 = 88%), and 0.47 (95% CI: 0.42–0.51, I2 = 56%), respectively. Compared to the success group, age, body mass index (BMI), Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE) II score, D-dimer, lactate, heart rate, and respiratory rate were higher and PaO2, PaO2/FiO2, ROX index (the ratio of SpO2/FiO2 to respiratory rate), ROX index after the initiation of HFNC, and duration of HFNC were lower in the failure group (all Ps < 0.05). There were also more smokers and more comorbidities in the failure group (all Ps < 0.05). Pooled odds ratios (ORs) revealed that older age (OR: 1.04, 95% CI: 1.01–1.07, P = 0.02, I2 = 88%), a higher white blood cell (WBC) count (OR: 1.06, 95% CI: 1.01–1.12, P = 0.02, I2 = 0%), a higher heart rate (OR: 1.42, 95% CI: 1.15–1.76, P < 0.01, I2 = 0%), and a lower ROX index(OR: 0.61, 95% CI: 0.39–0.95, P = 0.03, I2 = 93%) after the initiation of HFNC were all significant risk factors for HFNC failure. Conclusions: HFNC is an effective way of providing respiratory support in the treatment of COVID-19 patients. Older age, a higher WBC count, a higher heart rate, and a lower ROX index after the initiation of HFNC are associated with an increased risk of HFNC failure.

show abstract

High flow nasal oxygen (HFNO) in the treatment of COVID-19 infection of adult patients from – An emergency perspective: A systematic review and meta-analysis

Shallik¹,

Bashir²,

Elmoheen³

et al. 2023

Trends in Anaesthesia and Critical Care

View full text Add to dashboard Cite

Clinical experience with high-flow nasal cannulas for coronavirus disease 2019 patients in Japan

Cited by 10 publications

References 10 publications

High-flow nasal cannula oxygen therapy in hypoxic patients with COVID-19 pneumonia: A retrospective cohort study confirming the utility of respiratory rate index

High-flow nasal cannula oxygen therapy in hypoxic patients with COVID-19 pneumonia: A retrospective cohort study confirming the utility of respiratory rate index

Effectiveness of the use of a high-flow nasal cannula to treat COVID-19 patients and risk factors for failure: a meta-analysis

High flow nasal oxygen (HFNO) in the treatment of COVID-19 infection of adult patients from – An emergency perspective: A systematic review and meta-analysis

Contact Info

Product

Resources

About